CN109394788A - 宠物补血肝精口服液及其制备方法 - Google Patents
宠物补血肝精口服液及其制备方法 Download PDFInfo
- Publication number
- CN109394788A CN109394788A CN201811596918.1A CN201811596918A CN109394788A CN 109394788 A CN109394788 A CN 109394788A CN 201811596918 A CN201811596918 A CN 201811596918A CN 109394788 A CN109394788 A CN 109394788A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- pet
- essence
- oral liquor
- enriched blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 23
- 239000008280 blood Substances 0.000 title claims abstract description 23
- 229940040511 liver extract Drugs 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- 208000007502 anemia Diseases 0.000 claims abstract description 16
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 15
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 15
- 229960002413 ferric citrate Drugs 0.000 claims abstract description 15
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims abstract description 15
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 14
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 14
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 14
- 239000004471 Glycine Substances 0.000 claims abstract description 13
- 108010011485 Aspartame Proteins 0.000 claims abstract description 11
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960003438 aspartame Drugs 0.000 claims abstract description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 11
- 235000010357 aspartame Nutrition 0.000 claims abstract description 11
- 239000000605 aspartame Substances 0.000 claims abstract description 11
- 229960005337 lysine hydrochloride Drugs 0.000 claims abstract description 11
- 229930182817 methionine Natural products 0.000 claims abstract description 11
- 239000011570 nicotinamide Substances 0.000 claims abstract description 11
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 11
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 11
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 10
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 10
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 10
- 230000004060 metabolic process Effects 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 229960004452 methionine Drugs 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 abstract description 3
- 239000011720 vitamin B Substances 0.000 abstract description 3
- 229940046001 vitamin b complex Drugs 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 241000282326 Felis catus Species 0.000 description 6
- 239000007788 liquid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- UMEAURNTRYCPNR-UHFFFAOYSA-N azane;iron(2+) Chemical compound N.[Fe+2] UMEAURNTRYCPNR-UHFFFAOYSA-N 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000021238 nutrient digestion Nutrition 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
宠物补血肝精口服液,包括以下百分比含量的原料,牛骨髓提取物0.5%~3.0%、柠檬酸铁铵0.3%~2.0%、赖氨酸盐酸盐0.03%~0.06%、蛋氨酸0.03%~1.0%、甘氨酸0.03%~1.0%、维生素B10.03%~0.1%、维生素B2 0.01%~0.1%、维生素B60.01%~0.1%、烟酰胺0.01%~0.1%、泛酸钙0.001%~0.01%、阿斯巴甜0.01%~0.1%、香精0.01%‑0.1%、一水柠檬酸0.1%~0.5%、苯甲酸钠0.1%~0.5%、纯化水90.4%‑98.8%;采用柠檬酸铁铵,治疗缺铁性贫血;添加泛酸钙,促进新陈代谢;添加维生素B族和甘氨酸,补充能量及吸收。
Description
技术领域
本发明涉及动物医药领域,尤其涉及宠物补血肝精口服液及其制备方法。
背景技术
随着社会经济的发展和城市化进程的加速,人们精神生活与物质生活不断改善,社会老龄化步伐加快,独生子女家庭普及等客观因素的突出,人们的休闲、消费和情感寄托方式也呈多样化发展。饲养宠物成为众多家庭的消遣方式,随着宠物需求数量的日益增多,宠物产业也逐渐发展壮大。
随着宠物市场诞生后人们饲养宠物观念的逐渐普及,中国宠物行业经过二十多年的发展已逐渐形成规模。2012-2017年我国宠物行业市场规模不断扩大,年均复合增长达到34.26%,增长十分迅速。据统计2017年中国宠物行业市场规模达到1470亿元,同比增长20.5%。尽管近年来我国宠物行业市场规模增速有所放缓,但仍然能保持高于20%的增速。
宠物市场在发展,宠物的各种需求带动了宠物市场发展。贫血是猫犬常见病症,犬猫贫血是指全身循环血液中红细胞总量减少至正常值以下的异常症状。该病症临床表现以粘膜苍自、心率和呼吸加快、全身无力等特征。如果犬猫出现贫血现象,影响的不仅是您家狗狗或猫猫的活跃状态、而且会增加各种疾病的患病机率。
犬猫贫血原因:
1、出血性贫血:细小病毒、急性肠炎引起拉血、外伤或手术造成大出血;
2、溶血性贫血:各种原因引起红细胞大量破坏导致的贫血;蜱虫叮咬后引起的巴贝虫感染(钩端螺旋体病、疱疹病素、锥虫、溶血性链球菌等)、幼犬和母犬血型的不同而引发;
3、营养性贫血:缺乏某些造血物质,影响红细胞和血红蛋白的生成而发生的贫血为营养性贫血;多见于年幼犬猫以及孕期母宠,由于采食量不够和食物营养不均衡引起;
4、肝功能障碍:肝脏是绝大多数营养物质消化、吸收、代谢和贮存的场所,也涉及大量毒素、激素和有害异物的脱毒、分解代谢和排泄,各种有毒物质和化学药品,如铜、砷、汞、硒、氯仿、鞣酸、黄曲霉和四氯化碳等以及病毒、细菌、生虫感染及药物过敏可引起中毒性肝炎贫血是宠物肝病的一个主要症状,此时我们需要及时给犬猫补充营养,喂食补血养肝液。
发明内容
本发明目的是提供宠物补血肝精口服液及其制备方法,采用添加泛酸钙,促进新陈代谢;添加维生素B族和甘氨酸,补充能量并且促进吸收。能克服现有技术存在的上述问题。
为了实现上述技术目的,达到上述的技术要求,本发明所采用的技术方案是:宠物补血肝精口服液,其特征在于:包括以下百分比含量的原料,牛骨髓提取物 0.5%~3.0%、柠檬酸铁铵0.3%~2.0%、赖氨酸盐酸盐0.03%~0.06%、蛋氨酸0.03%~1.0%、甘氨酸0.03%~1.0%、维生素B10.03%~0.1%、维生素B2 0.01%~0.1%、维生素B60.01%~0.1%、烟酰胺0.01%~0.1%、泛酸钙0.001%~0.01%、阿斯巴甜0.01%~0.1%、香精0.01%-0.1%、一水柠檬酸0.1%~0.5%、苯甲酸钠0.1%~0.5%、纯化水90.4%-98.8%。
优选的:所述的香精为牛肉香精、牛奶香精、鸡肉香精;
优选的:所述的柠檬酸铁铵,作为铁强化剂和补血剂,以治疗缺铁性贫血;
优选的:所述的泛酸钙用以促进新陈代谢;
优选的:所述的维生素B1、维生素B2、维生素B6和甘氨酸用以补充能量并且促进吸收。
宠物补血肝精口服液的制备方法,其特征在于:包括如下步骤:
a.称取所需百分比含量的原料;
b.向所取纯化水中依次加入牛骨髓提取物、柠檬酸铁铵、赖氨酸盐酸盐、蛋氨酸、甘氨酸、维生素B1、维生素B2、维生素B6、烟酰胺、泛酸钙、阿斯巴甜,搅拌均匀,得到混合物A;
c.向混合物A中加入香精、一水柠檬酸、苯甲酸钠,搅拌均匀即可;
d.过滤;
e.灭菌;
f.采用100ml玻璃瓶分装。
有益效果;宠物补血肝精口服液及其制备方法,与现有补血肝精补充剂相比:具有如下的优点:本发明宠物补血肝精口服液用柠檬酸铁铵,作为铁强化剂和补血剂,以治疗缺铁性贫血;加泛酸钙,促进新陈代谢;添加维生素B族和甘氨酸,补充能量并且促进吸收;采用液体形式制备,对肠胃刺激小,吸收快;本发明提供三种口味选择,适口性佳,使用方便。
具体实施方式
为了使本发明的发明目的、技术方案及其有益技术效果更加清晰,以下结合具体实施方式,对本发明进行进一步详细说明;
宠物补血肝精口服液,其特征在于:包括以下百分比含量的原料,牛骨髓提取物 0.5%~3.0%、柠檬酸铁铵0.3%~2.0%、赖氨酸盐酸盐0.03%~0.06%、蛋氨酸0.03%~1.0%、甘氨酸0.03%~1.0%、维生素B10.03%~0.1%、维生素B2 0.01%~0.1%、维生素B60.01%~0.1%、烟酰胺0.01%~0.1%、泛酸钙0.001%~0.01%、阿斯巴甜0.01%~0.1%、香精0.01%-0.1%、一水柠檬酸0.1%~0.5%、苯甲酸钠0.1%~0.5%、纯化水90.4%-98.8%。
所述的香精为牛肉香精、牛奶香精、鸡肉香精;采用柠檬酸铁铵,作为铁强化剂和补血剂,以治疗缺铁性贫血;添加泛酸钙,促进新陈代谢;添加维生素B1、维生素B2、维生素B6和甘氨酸,补充能量并且促进吸收。
宠物补血肝精口服液的制备方法,其特征在于:包括如下步骤:
a.称取所需百分比含量的原料;
b.向所取纯化水中依次加入牛骨髓提取物、柠檬酸铁铵、赖氨酸盐酸盐、蛋氨酸、甘氨酸、维生素B1、维生素B2、维生素B6、烟酰胺、泛酸钙、阿斯巴甜,搅拌均匀,得到混合物A;
c.向混合物A中加入香精、一水柠檬酸、苯甲酸钠,搅拌均匀即可;
d.过滤;
e.灭菌;
f.采用100ml玻璃瓶分装。
本发明的具体实施:
实施例1
本发明的一种宠物补血肝精口服液,鸡肉口味,按下述重量份的组份组成,称取牛骨髓提取物 0.5%~3.0%、柠檬酸铁铵0.3%~2.0%、赖氨酸盐酸盐0.03%~0.06%、蛋氨酸0.03%~1.0%、甘氨酸0.03%~1.0%、维生素B10.03%~0.1%、维生素B2 0.01%~0.1%、维生素B60.01%~0.1%、烟酰胺0.01%~0.1%、泛酸钙0.001%~0.01%、阿斯巴甜0.01%~0.1%、鸡肉香精0.01%-0.1%、一水柠檬酸0.1%~0.5%、苯甲酸钠0.1%~0.5%、纯化水90.4%-98.8%。
实施例2
本发明的另一种宠物补血肝精口服液,牛奶口味,按下述重量份的组份组成,称取牛骨髓提取物 0.5%~3.0%、柠檬酸铁铵0.3%~2.0%、赖氨酸盐酸盐0.03%~0.06%、蛋氨酸0.03%~1.0%、甘氨酸0.03%~1.0%、维生素B10.03%~0.1%、维生素B2 0.01%~0.1%、维生素B60.01%~0.1%、烟酰胺0.01%~0.1%、泛酸钙0.001%~0.01%、阿斯巴甜0.01%~0.1%、鸡肉香精0.01%-0.1%、一水柠檬酸0.1%~0.5%、苯甲酸钠0.1%~0.5%、纯化水90.4%-98.8%。
实施例3
本发明的还有一种宠物补血肝精口服液,牛肉口味,按下述重量份的组份组成,称取牛骨髓提取物 0.5%~3.0%、柠檬酸铁铵0.3%~2.0%、赖氨酸盐酸盐0.03%~0.06%、蛋氨酸0.03%~1.0%、甘氨酸0.03%~1.0%、维生素B10.03%~0.1%、维生素B2 0.01%~0.1%、维生素B60.01%~0.1%、烟酰胺0.01%~0.1%、泛酸钙0.001%~0.01%、阿斯巴甜0.01%~0.1%、鸡肉香精0.01%-0.1%、一水柠檬酸0.1%~0.5%、苯甲酸钠0.1%~0.5%、纯化水90.4%-98.8%。
实施例1至3中宠物液体钙制备方法如下,步骤包括:
a.称取所需百分比含量的质量;
b.向所取纯化水中依次加入牛骨髓提取物、柠檬酸铁铵、赖氨酸盐酸盐、蛋氨酸、甘氨酸、维生素B1、维生素B2、维生素B6、烟酰胺、泛酸钙、阿斯巴甜,搅拌均匀,得到混合物A;
c.向混合物A中加入香精、一水柠檬酸、苯甲酸钠,搅拌均匀即可;
d.过滤;
e.灭菌;
f.采用100ml玻璃瓶分装。
喂食方法:直接喂食或添加于粮食、饮水中。
为了更好地说明本发明的优点,下面给出使用案例予以说明。
案例1
宠物信息:中华田园犬,雌性,2岁1个月
症状:生产后虚弱,全身无力
分析原因:产后贫血
治疗方案:补血肝精口服液直接滴舌头上,每天两次,每次1ml,连用一周,身体恢复。
案例2
宠物信息:泰迪犬,雄性,3岁2个月
症状:舌头、牙龈发白
分析原因:贫血
治疗方案:液体钙直接口服,每天两次,每次1ml,连用一周,一周后舌头、牙龈渐变红。
上述实施例仅仅是为清楚地说明本发明所作的描述,而并非对实施方式的限定,对于所属领域的技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动,这里无需也无法对所有的实施方式予以穷举,而由此所引申出的显而易见的变化或变动仍处于本发明的保护范围之中。
Claims (3)
1.宠物补血肝精口服液,其特征在于:包括以下百分比含量的原料,牛骨髓提取物0.5%~3.0%、柠檬酸铁铵0.3%~2.0%、赖氨酸盐酸盐0.03%~0.06%、蛋氨酸0.03%~1.0%、甘氨酸0.03%~1.0%、维生素B10.03%~0.1%、维生素B2 0.01%~0.1%、维生素B60.01%~0.1%、烟酰胺0.01%~0.1%、泛酸钙0.001%~0.01%、阿斯巴甜0.01%~0.1%、香精0.01%-0.1%、一水柠檬酸0.1%~0.5%、苯甲酸钠0.1%~0.5%、纯化水90.4%-98.8%。
2.根据权利要求1所述的宠物补血肝精口服液,其特征在于:所述的香精为牛肉香精、牛奶香精、鸡肉香精;采用柠檬酸铁铵,作为铁强化剂和补血剂,以治疗缺铁性贫血;添加泛酸钙,促进新陈代谢;添加维生素B1、维生素B2、维生素B6和甘氨酸,补充能量并且促进吸收。
3.根据权利要求1或2所述的宠物补血肝精口服液的制备方法,其特征在于:包括如下步骤:
a.称取所需百分比含量的原料;
b.向所取纯化水中依次加入牛骨髓提取物、柠檬酸铁铵、赖氨酸盐酸盐、蛋氨酸、甘氨酸、维生素B1、维生素B2、维生素B6、烟酰胺、泛酸钙、阿斯巴甜,搅拌均匀,得到混合物A;
c.向混合物A中加入香精、一水柠檬酸、苯甲酸钠,搅拌均匀即可;
d.过滤;
e.灭菌;
f.采用100ml玻璃瓶分装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811596918.1A CN109394788A (zh) | 2018-12-26 | 2018-12-26 | 宠物补血肝精口服液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811596918.1A CN109394788A (zh) | 2018-12-26 | 2018-12-26 | 宠物补血肝精口服液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109394788A true CN109394788A (zh) | 2019-03-01 |
Family
ID=65461675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811596918.1A Pending CN109394788A (zh) | 2018-12-26 | 2018-12-26 | 宠物补血肝精口服液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109394788A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110810630A (zh) * | 2019-12-13 | 2020-02-21 | 江苏益力达生物科技有限公司 | 一种宠物肝脏补血类营养口服液及其生产工艺 |
US20220273707A1 (en) * | 2021-02-24 | 2022-09-01 | MoxxiTech, LLC | Compositions and methods for treating canine parvovirus infection |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101125162A (zh) * | 2007-08-07 | 2008-02-20 | 江西本草天工科技有限责任公司 | 一种补血的药物制剂及其制备方法 |
CN101704738A (zh) * | 2009-11-25 | 2010-05-12 | 郑州瑞普生物工程有限公司 | 柠檬酸铁铵的生产方法 |
CN102224893A (zh) * | 2011-05-05 | 2011-10-26 | 通化一洋保健品有限公司 | 保健口服液 |
CN103690561A (zh) * | 2014-01-20 | 2014-04-02 | 湖南康寿制药有限公司 | 一种口服液的制备方法 |
CN106858620A (zh) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | 一种贫血专用型临床营养配方及其制备方法 |
CN107510701A (zh) * | 2017-08-24 | 2017-12-26 | 湖南知达医药科技有限公司 | 一种儿童补铁与维生素的组合物及其制备方法和应用 |
CN107952066A (zh) * | 2017-11-20 | 2018-04-24 | 江苏雅博动物健康科技有限责任公司 | 一种宠物液体钙及其制备方法 |
CN109123036A (zh) * | 2018-08-06 | 2019-01-04 | 广州灵润生物科技有限公司 | 大豆-骨髓多肽组合物及应用 |
-
2018
- 2018-12-26 CN CN201811596918.1A patent/CN109394788A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101125162A (zh) * | 2007-08-07 | 2008-02-20 | 江西本草天工科技有限责任公司 | 一种补血的药物制剂及其制备方法 |
CN101704738A (zh) * | 2009-11-25 | 2010-05-12 | 郑州瑞普生物工程有限公司 | 柠檬酸铁铵的生产方法 |
CN102224893A (zh) * | 2011-05-05 | 2011-10-26 | 通化一洋保健品有限公司 | 保健口服液 |
CN103690561A (zh) * | 2014-01-20 | 2014-04-02 | 湖南康寿制药有限公司 | 一种口服液的制备方法 |
CN106858620A (zh) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | 一种贫血专用型临床营养配方及其制备方法 |
CN107510701A (zh) * | 2017-08-24 | 2017-12-26 | 湖南知达医药科技有限公司 | 一种儿童补铁与维生素的组合物及其制备方法和应用 |
CN107952066A (zh) * | 2017-11-20 | 2018-04-24 | 江苏雅博动物健康科技有限责任公司 | 一种宠物液体钙及其制备方法 |
CN109123036A (zh) * | 2018-08-06 | 2019-01-04 | 广州灵润生物科技有限公司 | 大豆-骨髓多肽组合物及应用 |
Non-Patent Citations (1)
Title |
---|
薛芳等主编: "《中国药物大全 中药卷》", 31 January 1998, 北京:人民卫生出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110810630A (zh) * | 2019-12-13 | 2020-02-21 | 江苏益力达生物科技有限公司 | 一种宠物肝脏补血类营养口服液及其生产工艺 |
US20220273707A1 (en) * | 2021-02-24 | 2022-09-01 | MoxxiTech, LLC | Compositions and methods for treating canine parvovirus infection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ashmead | The absorption and metabolism of iron amino acid chelate | |
CN102935231A (zh) | 使用瓜氨酸的治疗 | |
CN108157953A (zh) | 一种全营养配方食品及其制备方法 | |
CN109394788A (zh) | 宠物补血肝精口服液及其制备方法 | |
Elaref et al. | Influence of dietary supplementation of yeast on milk composition and lactation curve behavior of Sohagi ewes, and the growth performance of their newborn lambs | |
CN106889327A (zh) | 一种乳猪奶粉及其制备方法 | |
Schott II et al. | Treatments affecting fluid and electrolyte status during exercise | |
US9474292B1 (en) | Nutritional powder including brewer's yeast, aronia extract, and cranberry extract for animals | |
US20160095894A1 (en) | Dietetic multi-component system | |
CN106615689A (zh) | 一种提高弱僵猪生产性能的肠道保健剂及其制备方法和使用方法 | |
KR20020092082A (ko) | 자양강장제 조성물 | |
CN109007355A (zh) | 一种改善营养不良性贫血的功能性饲料 | |
Smart et al. | Effects of early-life undernutrition in artificially reared rats: subsequent body and organ growth | |
CN103975896B (zh) | 降低半散养传统黑猪肉质中重金属抗生素残留的饲养方法 | |
CN114431340A (zh) | 儿茶素制备动物饲料添加剂的应用及其饲料 | |
CN111264707A (zh) | 一种育肥期水牛专用舔砖及其制备方法 | |
Naclerio et al. | Effectiveness of whey protein supplement in resistance trained individuals | |
CN107647122B (zh) | 一种用于育肥肉牛的中草药复合饲料添加剂 | |
CN107510701B (zh) | 一种儿童补铁与维生素的组合物及其制备方法和应用 | |
Fairweather-Tait | Trace element bioavailability | |
AU2006262999B2 (en) | Parenteral selenomethionine for production of selenium-rich foods | |
RU2368251C2 (ru) | Пищевая и кормовая добавки и их применение | |
CN108935701A (zh) | 一种提高免疫力的羊奶粉、羊奶粉的制备方法及应用 | |
CN1579233A (zh) | 一种含水苏糖的补钙保健食品 | |
CN108740355A (zh) | 宠物用营养膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190301 |
|
RJ01 | Rejection of invention patent application after publication |